Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune ThrombocytopeniaDavid J. Kuter, Nichola Cooper, Eun‐Ju Lee et al.|Blood|2019Cited by 16